Biology Atlas

Map / Assays

assay · intermediate · partly written

Hepatocyte stability assay

Whole liver cells are incubated with a compound and parent depletion gives intrinsic clearance, with uptake transporters and conjugation enzymes present.

Also called: hepatocyte clearance

How well it predicts: the numbers depend on the dataset more

Human hepatocytes, 101 drugs, well-stirred model: average fold error 2.7, 30.7 percent within 2-fold and 62.4 percent underpredicted; by extraction class (n=55, 28, 18) the fold error was 2.1, 3.2 and 4.8 and the share within 2-fold 34.6, 35.7 and 11.1 percent; only 1 of 18 high-extraction drugs was classified as high. An older database found a bias of about 5-fold for microsomes and 4-fold for hepatocytes, with the parallel-tube model helping only marginally. In a blinded multi-company set of 19 drugs with intravenous data, hepatocyte prediction without binding was within 2-fold for 78 percent, and the best methods reached 78 percent within 2-fold, 94 percent within 3-fold and 100 percent within 10-fold. One company reported about 71 percent of key PK parameters within 2-fold across 116 candidates, self-reported. 1234

Contested

Why it misses more

The authors of the 101-drug study propose cofactor depletion, loss of enzyme activity, permeability limits, the unstirred water layer and errors in protein binding, and call the mechanism undetermined. The high-extraction group contains only 2 drugs within 2-fold, so 11.1 percent is not a stable rate. 1

Reported, not yet replicated

Question answered

How fast intact liver cells remove the compound, including uptake and conjugation, so human hepatic clearance can be estimated. 1

Reported, not yet replicated

Readout physical

Remaining parent at set times, scaled per million cells; the same depletion readout as the microsomal assay. 1

Our inference

Not measured

Anything outside the liver, and the whole-liver behaviour the stirred-tank equation hides; standard assays predict poorly for low-turnover compounds (one vendor poster, overview only). 1

Reported, not yet replicated

Setting

Where in cascade

Still open here

Not yet written: Sample prep, Conditions, Throughput class, Throughput, Time per run, Cost, Engineerable variants, Use cases, Before after, Capital, Emerging, ML role, Data availability.

Linked from

Sources

  1. Bowman CM, Benet LZ. In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction. J Pharm Sci (2019). paper; opened 2026-11-17 all records citing this
  2. Hallifax D, Foster JA, Houston JB. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res (2010). paper; opened 2026-11-17 all records citing this
  3. Ring BJ, Chien JY, Adkison KK, Jones HM, et al.. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci (2011). paper; opened 2026-11-17 all records citing this
  4. Davies M, Jones RDO, Grime K, Jansson-Löfmark R, et al.. Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades. Trends Pharmacol Sci (2020). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)

This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-17
Record
content/assays/hepatocyte-stability-assay.json